Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03123796
Other study ID # 332
Secondary ID
Status Completed
Phase N/A
First received April 19, 2017
Last updated December 25, 2017
Start date December 2016
Est. completion date November 2017

Study information

Verified date December 2017
Source Istanbul University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Use of proton pump inhibitors (PPIs) is quite common among renal transplant recipients and reduced kidney functions and hypomagnesemia with the use of PPIs have been reported. In this study, investigation of the effects of PPI use on the outcome of kidney transplant recipients is aimed.


Description:

Use of proton pump inhibitors (PPIs) is frequent among renal transplant recipients due to the common use of glucocorticoids in immunosuppresive regimens after transplantation. Reduced kidney functions and hypomagnesemia with the use of PPIs have been reported in various patient populations. However, few studies examined the effects of PPIs on kidney transplant recipients. Therefore, the aim of this study is to investigate the effects of PPI and/or histamine H2 receptor antagonist use on serum magnesium levels, allograft functions and survival in kidney transplant recipients.


Recruitment information / eligibility

Status Completed
Enrollment 300
Est. completion date November 2017
Est. primary completion date September 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Kidney transplant recipients who used only proton pump inhibitors and did not use histamine H2 receptor antagonists (Only PPI).

- Kidney transplant recipients who used histamine H2 receptor antagonists and did not use proton pump inhibitors (Only H2RA).

- Kidney transplant recipients who used both proton pump inhibitors and histamine H2 receptor antagonists (PPI and H2RA).

- Kidney transplant recipients who used neither proton pump inhibitors nor histamine H2 receptor antagonists (No Acid Suppressive Treatment).

Exclusion Criteria:

- Patients who are unwilling or unable to consent.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Turkey Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Istanbul University

Country where clinical trial is conducted

Turkey, 

References & Publications (2)

Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Intern Med. 2016 Feb;176(2):238-46. doi: 10.1001/jamainternmed.2015.7193. — View Citation

van Boekel GA, Kerkhofs CH, van de Logt F, Hilbrands LB. Proton pump inhibitors do not increase the risk of acute rejection. Neth J Med. 2014 Feb;72(2):86-90. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Serum magnesium levels 5-10 years
Primary Graft survival 5-10 years
Secondary Graft rejection 5-10 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06025240 - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Recruiting NCT03855722 - Remote Ischaemic Preconditioning in Transplantation (RIPTRANS) N/A
Completed NCT03446196 - Hemodynamic Optimization During Single Kidney Transplantation With MostcareUP N/A
Completed NCT04019353 - Cf-DNA Assay During Treatment of Acute Rejection
Withdrawn NCT03314376 - Prehabilitation in Patients on a Waiting List for a Transplant N/A
Completed NCT04643665 - Prediction of Pulmonary Graft Dysfunction After Double-lung Transplantation (PGD3-AI Study)
Recruiting NCT03602807 - Safety and Effect of Low-Energy Extracorporeal Shockwave Therapy (ESWT) on the Renal Allograft in Transplant Recipients. N/A
Not yet recruiting NCT05951231 - Liver Transplantation After ex Vivo Liver Perfusion N/A